购物车
- 全部删除
- 您的购物车当前为空
Gemigliptin (LC15-0444) 是一种选择性的,可逆的,竞争性的二肽基肽酶 4 (DPP-4) 抑制剂,对人重组 DPP-4 的 IC50=10.3 nM。Gemigliptin 具有很强的抗糖基化活性,能够用于晚期糖基化终产物相关的糖尿病并发症的研究。
Gemigliptin (LC15-0444) 是一种选择性的,可逆的,竞争性的二肽基肽酶 4 (DPP-4) 抑制剂,对人重组 DPP-4 的 IC50=10.3 nM。Gemigliptin 具有很强的抗糖基化活性,能够用于晚期糖基化终产物相关的糖尿病并发症的研究。
规格 | 价格 | 库存 | 数量 |
---|---|---|---|
1 mg | ¥ 242 | 现货 | |
2 mg | ¥ 338 | 现货 | |
5 mg | ¥ 565 | 现货 | |
10 mg | ¥ 898 | 现货 | |
25 mg | ¥ 1,650 | 现货 | |
50 mg | ¥ 2,730 | 现货 | |
100 mg | ¥ 3,970 | 现货 | |
500 mg | ¥ 8,860 | 6-8周 | |
1 mL x 10 mM (in DMSO) | ¥ 755 | 现货 |
产品描述 | Gemigliptin (LC15-0444) is a potent dipeptidyl peptidase-4 (DPP-4) inhibitor(KD : 7.25 nM.) |
靶点活性 | DPP4:7.25 nM(KD) |
体外活性 | Gemigliptin attenuated vascular calcification and osteogenic trans-differentiation in vascular smooth muscle cells via multiple steps including downregulation of PiT-1 expression and suppression of reactive oxygen species generation, phospho-PI3K/AKT, and the Wnt signaling pathway[1].Gemigliptin treatment attenuated phosphorylated nuclear factor-κB levels, which had been increased in the UUO kidney as well as in TGF-β-treated cultured renal cells[2]. |
细胞实验 | Using immunohistochemical and Western blot analysis, Quantitated components of the NLRP3 inflammasome in kidneys with and without gemigliptin treatment, and in vitro in human kidney tubular epithelial human renal proximal tubule cells (HK-2) cells, further analyzed the effect of gemigliptin on transforming growth factor-β (TGF-β)-stimulated production of profibrotic proteins[2]. |
别名 | 吉格列汀酒石酸盐, 吉格列汀, LC15-0444 |
分子量 | 489.36 |
分子式 | C18H19F8N5O2 |
CAS No. | 911637-19-9 |
Smiles | N[C@H](CN1CC(F)(F)CCC1=O)CC(=O)N1CCc2c(C1)nc(nc2C(F)(F)F)C(F)(F)F |
密度 | 1.54 g/cm3 (Predicted) |
存储 | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. | |||||||||||||||||||||||||||||||||||
溶解度信息 | DMSO: 122.5 mg/mL (250.33 mM) | |||||||||||||||||||||||||||||||||||
溶液配制表 | ||||||||||||||||||||||||||||||||||||
DMSO
|
版权所有©2015-2024 TargetMol Chemicals Inc.保留所有权利.
评论内容